EX-99.1 2 dwtx-20260120xex99d1.htm EX-99.1 Exhibit 99.1 CEO Letter to Dogwood Therapeutics Shareholders: The Year in Review, The Year Ahead ALPHARETTA, Ga., January 20, 2026 -- Dogwood Therapeutics, Inc. (NASDAQ: DWTX) (“DWTX” or “Company”), a company that focuses on developing new non-opioid medicines to treat pain and neuropathy, issues a corporate update in the following Letter to Shareholders from CEO, Greg Duncan. Dear Shareholders, Dogwood Therapeutics is a development-stage biotechnology company with the ultimate goal of advancing the standard of care for patients suffering from cancer-related pain and neuropathy, two conditions where both patients and providers are in clear need of alternative treatment options. In 2025, the Company made extensive progress in expanding and advancing its pipeline of first-in-class new development candidates to treat cancer and chemotherapy induced pain and neuropathy. Highlights include: Recruitment of over 100 patients in the Halneuron® Phase 2b Chemotherapy Induced Pain (HALT-CINP) Study that enabled the execution of our interim analysis that determined the final study sample size and optimal analysis methodology. Expanded t…
Open exhibit ↗Current Report · Items 7.01, 9.01 · 8-K
Dogwood Therapeutics, Inc.
DWTXNASDAQEQUITYCurrent
Regulation FD Disclosure
Item 7.01 Regulation FD Disclosure. On January 20, 2026, the Company posted a shareholder letter to its website providing a corporate update. A copy of the shareholder letter is furnished as Exhibit 99.1.…
Company context
Dogwood Therapeutics (Nasdaq: DWTX) is a development-stage biopharmaceutical company focused on developing first-in-class, non-opioid medicines to treat pain and neuropathic disorders. Dogwood’s research pipeline includes two first-in-class development candidates, Halneuron® and SP16 IV. Our lead product candidate, Halneuron®, is in Phase 2b development to treat pain conditions including the neuropathic pain associated with chemotherapy treatment. Halneuron® has been granted fast track designation from the FDA for the treatment of CINP. Halneuron® is a non-opioid, NaV 1.7 analgesic which is a highly specific voltage-gated sodium channel modulator, a mechanism known to be effective for reducing pain transmission. In clinical studies, Halneuron® treatment has demonstrated pain reduction in pain related to general cancer and in pain related to chronic CINP.